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A B S T R A C T
Background
Neuropathic pain is a consequence of damage to the central nervous system (CNS), for example, cerebrovascular accident, multiple
sclerosis or spinal cord injury, or peripheral nervous system (PNS), for example, painful diabetic neuropathy (PDN), postherpetic
neuralgia (PHN), or surgery. Evidence suggests that people suffering from neuropathic pain are likely to seek alternative modes of
pain relief such as herbal medicinal products due to adverse events brought about by current pharmacological agents used to treat
neuropathic pain. This review includes studies in which participants were treated with herbal medicinal products (topically or ingested)
who had experienced neuropathic pain for at least three months.
Objectives
To assess the analgesic efficacy and effectiveness of herbal medicinal products or preparations for neuropathic pain, and the adverse
events associated with their use.
Search methods
We searched CENTRAL and the Cochrane Database of Systematic Reviews, MEDLINE, Embase, CINAHL and AMED to March
2018. We identified additional studies from the reference lists of the retrieved papers. We also searched trials registries for ongoing trials
and we contacted experts in the field for relevant data in terms of published, unpublished or ongoing studies.
Selection criteria
We included randomised controlled trials (including cross-over designs) of double-blind design, assessing efficacy of herbal treatments
for neuropathic pain compared to placebo, no intervention or any other active comparator. Participants were 18 years and above and
had been suffering from one or more neuropathic pain conditions, for three months or more.
We applied no restrictions to language or gender. We excluded studies monitoring effects of isolated, single chemicals derived from
the plant or synthetic chemicals based on constituents of the plant, if they were not administered at a concentration naturally present
within the plant.
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We excluded studies monitoring the effects of traditional Asian medicine and Cannabinoids as well as studies looking at headache or
migraine as these treatments and conditions are addressed in distinct reviews.
Data collection and analysis
We used standard methodological procedures expected by Cochrane. Two review authors independently considered trials for inclusion,
assessed risk of bias, and extracted data. We calculated the risk ratio (RR) and number needed to treat for an additional beneficial
outcome (NNTB). The primary outcomes were participant-reported pain relief of 30%, or 50%, or greater, and participant-reported
global impression of clinical change (PGIC). We also collected information on adverse events. We assessed evidence using GRADE
and created a ’Summary of findings’ table.
Main results
We included two studies (128 participants). Both diabetic neuropathy and non-diabetic neuropathic pain conditions were investigated
across these two studies.
Two herbal medicinal products, namely nutmeg (applied topically as a 125 mL spray for four weeks, containing mace oil 2%, nutmeg
oil 14%, methyl salicylate 6%, menthol 6%, coconut oil and alcohol) and St John’s wort (taken in capsule form containing 900 µg
total hypericin each, taken three times daily, giving a total concentration of 2700 mg for five weeks). Both studies allowed the use of
concurrent analgesia.
Both reported at least one pain-related outcome but we could not carry out meta-analysis of effectiveness due to heterogeneity between
the primary outcomes and could not draw any conclusions of effect. Other outcomes included PGIC, adverse events and withdrawals.
There were no data for participant-reported pain relief of 50% or greater or PGIC (moderate and substantial) outcomes.
When looking at participant-reported pain relief of 30% or greater over baseline, we observed no evidence of a difference (P = 0.64)
in response to nutmeg versus placebo (RR 1.12, 95% confidence interval (CI) 0.69 to 1.85; 48.6% vs 43.2%). We downgraded the
evidence for this outcome to very low quality.
We observed no change between placebo and nutmeg treatment when looking at secondary pain outcomes. Visual analogue scale (VAS)
scores for pain reduction (0 to 100, where 0 = no pain reduction), were 44 for both nutmeg and placebo with standard deviations of
21.5 and 26.5 respectively. There was no evidence of a difference (P = 0.09 to 0.33) in total pain score in response to St John’s wort
compared to placebo, as there was only a reduction of 1 point when looking at median differences in change from baseline on a 0 to
10-point numeric rating scale.
There was a total of five withdrawals out of 91 participants (5%) in the treatment groups compared to six of 91 (6.5%) in the placebo
groups, whilst adverse events were the same for both the treatment and placebo groups.
We judged neither study as having a low risk of bias. We attributed risk of bias to small study size and incomplete outcome data leading
to attrition bias. We downgraded the evidence to very low quality for all primary and secondary outcomes reported in this review. We
downgraded the quality of the evidence twice due to very serious limitations in study quality (due to small study size and attrition bias)
and downgraded a further level due to indirectness as the included studies only measured outcomes at short-term time points. The
results from this review should be treated with scepticism as we have very little confidence in the effect estimate.
Authors’ conclusions
There was insufficient evidence to determine whether nutmeg or St John’s wort has any meaningful efficacy in neuropathic pain
conditions.
The quality of the current evidence raises serious uncertainties about the estimates of effect observed, therefore, we have very little
confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect.
P L A I N L A N G U A G E S U M M A R Y
Herbal products for neuropathic pain
Background
Neuropathic pain is a complex and often disabling condition and many people suffer moderate or severe pain for many years, affecting
quality of life. This condition is difficult to treat and typically only 40% to 60% of people with this condition achieve partial relief.
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Neuropathic pain is pain coming from damaged nerves. It is different from pain messages that are carried along healthy nerves from
damaged tissue (for example, a fall or cut, or arthritic knee). Neuropathic pain is often treated by different medicines to those used for
pain from damaged tissue. Medicines that are sometimes used to treat neuropathic pain can have damaging side effects and therefore
people are now trying herbal products to help relieve pain instead.
We conducted a search for relevant clinical trials in March 2018. We looked for studies in adults suffering from moderate neuropathic
pain who took some form of herbal product, either by consuming it in their diet, in tablet form, or by applying it to the skin to relieve
pain. We also collected information on side effects these herbal products might have.
Study characteristics
We included two studies with 128 participants. Study size ranged from 54 to 74 participants with an age range of 21 to 85 years.
Both studies included men and women. Both studies compared herbal medicines (nutmeg or St John’s wort) to placebo and allowed
continued use of painkillers. Both studies reported side effects.
Key results
There were no reports from participants of any reduction in pain intensity of 30% or above and there was no observable reduction in
the total pain score in response to either nutmeg or St John’s wort. There were also no reductions in dropout rates or number of side
effects between the treatment and placebo.
Quality of the evidence
We rated the quality of the evidence from studies using four levels: very low, low, moderate, or high. Very low-quality evidence means
that we are very uncertain about the results. High-quality evidence means that we are very confident.
Only two small studies met this review’s search criteria. Neither provided any high-quality evidence for either possible benefits or harms.
We judged the evidence to be of very low quality. Thus, results from the studies contained in this review are very uncertain and prevent
any meaningful conclusions. Larger, high-quality studies are needed to assess accurately if herbal products are of any benefit or have
the potential to harm when used to treat adults with neuropathic pain.
3Herbal medicinal products or preparations for neuropathic pain (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Herbal treatment compared with placebo for adults with neuropathic pain
Patient or population: adults with neuropathic pain
Settings: primary care centre, hospital research unit
Intervention: herbal treatment
Comparison: placebo
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* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95%CI).
CI: conf idence interval; RR: risk rat io
GRADE Working Group grades of evidence
High quality: we are very conf ident that the true ef fect lies close to that of the est imate of the ef fect.
Moderate quality: we are moderately conf ident in the ef fect est imate; the true ef fect is likely to be close to the est imate of ef fect, but there is a possibility that it is substant ially
dif f erent.






































































































Very low quality: we have very lit t le conf idence in the ef fect est imate; the true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
aDowngraded twice for very serious study lim itat ions due to risk of bias: small populat ion (< 50 per treatment arm) and
incomplete outcome data (> 10%).
bDowngraded once for indirectness, outcomes only reported at short-term time points.
cNot downgraded for imprecision.
dNot downgraded for publicat ion bias, only 1 study ident if ied but thorough search strategy carried out.
eNot downgraded for inconsistency, I2 = 0%, P = 0.37, conf idence intervals overlap







































































































B A C K G R O U N D
Description of the condition
The International Association for the Study of Pain (IASP) classi-
fies neuropathic pain according to three features: the underlying
disease; the site of the lesion (i.e. a peripheral nerve lesion or spinal
cord); and the underlying mechanism (IASP 2006). It is defined
as, “Pain arising as a direct consequence of a lesion or disease af-
fecting the somatosensory system” (IASP 2006). Unlike nocicep-
tive pain, such as gout and other forms of arthritis, neuropathic
pain is caused by nerve damage, often accompanied by anatomical
and physiological changes in the central nervous system (CNS) or
peripheral nervous system (PNS). The pain can be described as
burning, tingling, shooting, stabbing or shocking. Injury to the
brain, brain tumours, diabetic neuropathy and herpes zoster are
all examples of conditions that may cause this type of pain.
Neuropathic pain can be very difficult to treat, with only 40%
to 60% of patients achieving partial relief (Dworkin 2007),
fewer than those experiencing nociceptive pain. Determining
the best treatment for individual patients remains challenging,
with favoured treatments including certain antidepressants, such
as tricyclics and selective serotonin-norepinephrine reuptake in-
hibitors (SNRIs), anticonvulsants, especially pregabalin (Lyrica)
and gabapentin (Neurontin), and topical lidocaine.
A study carried out in 1998 in the USA reported that ap-
proximately four million people suffered from neuropathic pain
(Dickson 2010). The highest prevalence rates were observed for
peripheral diabetic neuropathy (600,000 cases) and postherpetic
neuralgia (500,000 cases), based on a population of 270 million
(Bennett 1998). In Europe, neuropathic pain is estimated to af-
fect between 3% and 8% of individuals, with 5% of these peo-
ple reporting moderate to severe pain leading to significant reduc-
tions in quality of life (Bouhassira 2008; Gustorff 2008; Torrance
2006). In the UK, the prevalence of neuropathic pain is as high
as 8% (Torrance 2006), with incidence rate estimates for specific
conditions of 34 to 40 cases per 100,000 person-years observation
for postherpetic neuralgia and 27 to 400 cases for trigeminal neu-
ralgia, one for phantom limb pain and 15 to 400 cases of painful
diabetic neuropathy. While rates for phantom limb pain and pos-
therpetic neuralgia appear to have declined in recent years, painful
diabetic neuropathy has increased (Hall 2006; McQuay 2007).
Anatomical and physiological changes in the CNS include age-
dependent total grey matter volume decrease, reduced presynap-
tic dopamine activity, disruption of dopaminergic neurotransmis-
sion resulting in increased pain and discomfort, hippocampus dys-
function, and metabolite and cerebral metabolite ratio abnormal-
ities, all of which demonstrate CNS dysfunction (Emad 2008;
Kuchinad 2007; Petrou 2008; Wood 2007a; Wood 2007b; Wood
2009). People with chronic neuropathic display features of the cen-
tral hypersensitivity responsible for enhanced neuronal excitability
and increased pain (Curatolo 2006).
For the purpose of this review, the definition of ’neuropathic pain’
will be restricted to those disorders with a primary aetiology clearly
related to the PNS or CNS.
Pharmacological interventions include unconventional analgesics
such as antidepressants and anticonvulsants, in addition to con-
ventional medications such as strong opioids. Most of these agents
have significant side effects and as one of the first-line treatment
options there are concerns about the associated costs to the health
service (NICE 2010). Population-based surveys suggest that peo-
ple with chronic neurological pain are likely to try complemen-
tary and alternative (CAM) therapies such as herbal treatments
(Kanodia 2010; Metcalfe 2010; Thomas 2004). For this reason,
it is important for policy makers to become aware of the impact
these products may have.
Description of the intervention
Oral herbal remedies include standardised extracts (encapsulated
or tablet form), tinctures (e.g. alcohol, glycerine), dried herbs (en-
capsulated or tablet form), raw whole herb infusions (e.g. tea)
and decoctions (e.g. boiled down tea). Topical herbal applications
include ointments, essential oils, creams (petroleum or glycerine
based), powders, plasters and poultices. Constituents of a single
plant or of herbal mixtures are claimed to work synergistically to
produce a greater effect than a single constituent. It is also claimed
that the combined actions of the various constituents reduce the
toxicity of the extract compared with single, isolated constituents
(Ernst 2001). Both these synergistic and buffering effects extend
to the use of different plant extracts in combination preparations.
Three definitions of herbal medicines have been identified to
inform this review. Ernst 2001 has previously defined herbal
medicine as “The medical use of preparations that contain ex-
clusively plant material”. Gagnier 2011 defined herbal treatments
as all or part of a plant used for medicinal purposes, adminis-
tered orally (ingestion) or applied topically. This definition does
not include plant substances that are smoked (e.g. Cannabis
sativa), individual chemicals that are derived from plants or syn-
thetic chemicals that are based on constituents of plants. The
European Medicines Agency Directive (2004/24/EC) defines a
herbal medicinal product as “Any medicinal product, exclusively
containing as active ingredients, one or more herbal substances
or one or more herbal preparations, or one or more such herbal
substances in combination with one or more such herbal prepara-
tions”. Herbal preparations are defined as preparations obtained
by subjecting herbal substances to treatments such as extraction,
distillation, expression, fractionation, purification, concentration
or fermentation.
In the current review, we included herbal preparations that con-
tained whole plants, parts of plants, or comminuted or pow-
dered herbal substances, tinctures, extracts, essential oils, expressed
juices, processed exudates, infusions or decoctions. To clarify, we
included preparations exclusively containing plant material that
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were ingested or applied topically, at any dose and that contained
active ingredients of one or more herbal substance or preparation.
We defined herbal preparations as outlined by the EMA Directive
above.
Current guidelines on the treatment and management of neuro-
pathic pain do not report on the use of herbal products for pain in-
tensity reduction, possibly due to a lack of research studies. How-
ever, there is a body of literature suggesting a pain-reducing ef-
fect in response to cannabis that is being investigated in a separate
Cochrane Review (Mücke 2016). There is also some preliminary
evidence that capsaicin is beneficial for reduction of pain intensity
in people with some neuropathic pain conditions, as demonstrated
in two recent Cochrane Reviews (Derry 2012; Derry 2013). This
was based on studies of adequate methodological quality and in-
volved pooling of the neuropathic conditions (postherpetic neural-
gia, diabetic neuropathy, HIV neuropathy, postmastectomy pain
and postsurgical cancer pain). Whole essential oils have also been
reported to have analgesic effects in neuropathic pain in a ran-
domised, double-blind, placebo-controlled trial of 60 participants
(Li 2010). These preliminary results appear promising for the use
of herbal products/preparations in the treatment of neuropathic
pain, however more robust evidence is required before definitive
guidance on their use can be recommended.
Why it is important to do this review
Neuropathic pain is a complex and often disabling condition.
Many people suffer moderate or severe pain for many years, and in
the UK 7% to 8% of adults currently have chronic pain with neu-
ropathic characteristics (EFIC 2015), which leads to significant
reductions in quality of life. In a UK study, 17% of people who had
neuropathic pain characteristics had health-related quality of life
(QOL) scores equivalent to ’worse than death’ (Torrance 2014).
Conventional analgesics are usually not effective in alleviating the
symptoms, although opioids may be effective in some individuals.
Treatment is therefore usually by unconventional analgesics such
as antidepressants or antiepileptics. However, there has been neg-
ative publicity surrounding the side effects associated with current
pharmacological treatments for specific types of neuropathic pain
(BNF 2006; Glassman 1998; Peretti 2000), and evidence from
population-based surveys has shown that people with chronic pain
are likely to try herbal treatments. It is therefore important to de-
termine the efficacy and safety of herbal medicines in the treat-
ment of such conditions.
New standards have evolved for assessing efficacy in neuropathic
pain. More strict criteria for the inclusion of trials and assessment
of outcomes are now applied, and researchers are more aware of
problems that may affect overall assessment. For this reason, a re-
view applying these new standards to an assessment of the efficacy
of herbal medicinal products or preparations in neuropathic pain
is necessary.
O B J E C T I V E S
To assess the analgesic efficacy and effectiveness of herbal medicinal
products or preparations for neuropathic pain, and the adverse
events associated with their use.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised controlled trials (RCTs), including cross-over de-
signs, of double-blind design, which assess the efficacy and effec-
tiveness of herbal medicinal products or preparations for neuro-
pathic pain.
We applied no restriction with regard to language.
Types of participants
We included adult participants aged 18 years and above. Partici-
pants had been suffering from one or more neuropathic pain con-
ditions, for three months or more. Neuropathic pain conditions
included (but were not limited to) the following.
• Painful diabetic neuropathy (PDN)
• Post-herpetic neuralgia (PHN)
• Trigeminal neuralgia
• Phantom limb pain
• Postoperative or traumatic neuropathic pain
• Complex regional pain syndrome (CRPS)
• Cancer-related neuropathy
• HIV neuropathy
• Spinal cord injury
We included studies of participants with more than one type of
neuropathic pain with the intention of analysing these results ac-
cording to the primary condition.
We did not make restrictions based on gender.
We excluded studies of headache or migraine.
Types of interventions
For the purpose of this review, we included studies that investi-
gated the effects of herbal medicinal products or preparations ad-
ministered in the form of whole plants, parts of plants or extracts
for the relief of neuropathic pain compared to placebo, no inter-
vention or any other active comparator. These preparations were
either administered topically or orally. In the case of single, iso-
lated substances, we only included studies using a treatment dose
of the herbal product/preparation that was directly proportionate
to the concentration that would be present in the whole plant.
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We also extracted data from dose-comparison studies.
Co-interventions
We included studies monitoring other analgesic consumption,
alongside herbal medicinal products.
Exclusions
• Studies monitoring the effects of isolated, single chemicals
derived from the plant or synthetic chemicals based on
constituents of the plant if they were not being administered at a
concentration that would be naturally present within the plant.
• Studies monitoring the effects of traditional Asian medicine
as this involves complex mixtures of plant products
individualised for the patient.
• Studies monitoring the effects of capsaicin or cannabis as
these have been dealt with in separate Cochrane Reviews.
Types of outcome measures
We required studies to report pain assessment as either the primary
or secondary outcome. The majority of studies used standard sub-
jective scales for pain intensity or pain reduction, or both.
We considered the IMMPACT definitions of moderate and sub-
stantial benefit in chronic pain studies (Dworkin 2008).
Primary outcomes
• Participant-reported pain relief of 30% or greater, over
baseline (moderate)
• Participant-reported pain relief of 50% or greater, over
baseline (substantial)
• Participant-reported global impression of clinical change
(PGIC) much or very much improved (moderate)
• Participant-reported global impression of clinical change
(PGIC) very much improved (substantial)
Secondary outcomes
• Any pain-related outcome indicating some improvement
• Withdrawals: for any reason, due to lack of efficacy, due to
adverse events
• Adverse events: participant reporting of any adverse event;
participant reporting of any serious adverse event; death
We collected outcome assessment data for all treatment durations
and reported the extracted data.
Search methods for identification of studies
Electronic searches
To identify studies for inclusion in this review, we developed de-
tailed search strategies for each electronic database to be searched.
These were based on the search strategy developed for MED-
LINE but revised appropriately for each database. The search
strategy combined the subject search with phase one and two of
the Cochrane highly sensitive search strategy for RCTs (Lefebvre
2011), and was developed with the assistance of Cochrane Pain,
Palliative and Supportive Care’s (PaPaS) Information Specialist.
We undertook the latest search in March 2018. The subject search
used a combination of controlled vocabulary and free-text terms.
The search strategies used can be found in Appendix 1, Appendix
2, Appendix 3, Appendix 4 and Appendix 5.
We searched:
• the Cochrane Central Register of Controlled Trials
(CENTRAL; 2018, Issue 2) in the Cochrane Library;
• the Cochrane Database of Systematic Reviews (CDSR; 2018,
Issue 3) in the Cochrane Library;
• MEDLINE - OVID (1946 to 13 March 2018);
• Embase - OVID (1974 to 13 March 2018);
• CINAHL - EBSCO (1982 to 13 March 2018);
• AMED - OVID (1985 to 13 March 2018).
Searching other resources
We screened any systematic reviews on the effectiveness or efficacy
(or both) of herbal medicinal products or preparations for neu-
ropathic pain for additional references and identified additional
studies from the reference lists of the retrieved papers. We also
supplemented the electronic search strategy by using the Science
Citation Index to perform citation tracking of the RCTs identi-
fied.
We also searched the metaRegister of controlled trials (mRCT) (
http://www.controlled-trials.com/mrct ( at March 2019, this web-
site is under review)), Clinicaltrials.gov ( www.clinicaltrials.gov)
and the WHO International Clinical Trials Registry platform (
ICTRP) ( apps.who.int/trialsearch/) for ongoing trials. We carried
out the last search in March 2018.
We contacted experts in the field (identified by personal contacts,
lead authors in published studies, world wide web searching) for
relevant data in terms of published, or ongoing studies, to identify
other relevant articles that may have been missed by the electronic
search.
We also intended to identify herbal medicinal products or prepa-
rations being used without sufficient evidence of effectiveness (un-
published data) by contacting experts in the field of complemen-
tary and alternative medicine but it decided it was not productive
to do this for the purposes of the review at this stage as most experts
in the field appeared to be investigating those preparations that
we had chosen to exclude from this review, namely cannabis and
capsaicin at higher levels not present naturally in chili peppers. We
plan to revisit this decision in the future.
Our searches identified all relevant studies irrespective of language.
We assessed non-English papers and translated them with the as-
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sistance of a native speaker.
Data collection and analysis
Selection of studies
Two review authors (AB, CB) independently selected trials for in-
clusion and screened the titles and abstracts of publications ob-
tained by the search strategy. If no abstract was available we ob-
tained and assessed the full paper. We retrieved all trials classified
as relevant by either of the review authors for further assessment.
We resolved disagreement between review authors by consensus,
or third party adjudication (SMcD). We included a PRISMA flow
chart in this review, which shows the status of identified stud-
ies (Moher 2009), as recommended in the Cochrane Handbook of
Systematic Reviews of Interventions (Schünemann 2011). We in-
cluded studies in this review irrespective of whether measured out-
come data were reported in a ’usable’ way. Where necessary, we
attempted to contact primary authors for clarification of study
characteristics.
Data extraction and management
Two review authors (AB, DH) extracted data independently us-
ing a customised form, tested prior to use. We used this to ex-
tract relevant data on methodological issues, eligibility criteria,
interventions (including the pain condition, number of partici-
pants treated, herbal medicinal product/preparation, dosing reg-
imen, study design, study duration and follow-up, comparisons,
outcome measures and results, withdrawals and adverse events).
Again, we resolved any disagreement by consensus, or third party
adjudication (SMcD). We attempted to contact the primary study
authors to clarify any omitted data or study characteristics. With
the intention-to-treat analysis in mind, we extracted data accord-
ing to the original allocation groups, and noted losses to follow-
up where possible.
Where data seemed to be missing from a study we attempted to
obtain these data through correspondence with the study authors.
There was no blinding to study author, institution or journal at
this stage.
We collected characteristics of the included studies in sufficient
detail to populate a table of ’Characteristics of included studies’ in
this review.
Assessment of risk of bias in included studies
Two authors (AB and CB) independently assessed the risk of bias
for each study, using the ’Risk of bias’ tool available in the Review
Manager 5 (RevMan 5) software (Review Manager 2014), out-
lined in the Cochrane Handbook for Systematic Reviews of Interven-
tions (Higgins 2017), and adapted from those used by Cochrane
Pregnancy and Childbirth. We resolved any disagreements by dis-
cussion, with SMcD acting as third party adjudicator. We assessed
the following for each study.
• Random sequence generation (checking for possible
selection bias). We assessed the method used to generate the
allocation sequence as: low risk of bias (any truly random
process, e.g. random number table; computer random number
generator); unclear risk of bias (method used to generate
sequence not clearly stated); we excluded any studies at high risk
of bias (studies using a non-random process such as odd or even
date of birth).
• Allocation concealment (checking for possible selection
bias). The method used to conceal allocation to interventions
prior to assignment determines whether intervention allocation
could have been foreseen in advance of, or during recruitment,
or changed after assignment. We assessed the methods as: low
risk of bias (e.g. telephone or central randomisation;
consecutively numbered sealed opaque envelopes); unclear risk
of bias (method not clearly stated); we excluded any studies at
high risk of bias (studies that do not conceal allocation).
• Blinding of participants and personnel (checking for
possible performance bias). We assessed the methods used to
blind study participants and personnel from knowledge of which
intervention a participant received. We assessed methods as: low
risk of bias (study states that it was blinded and describes the
method used to achieve blinding, such as identical tablets
matched in appearance or smell, or a double-dummy technique);
unclear risk of bias (study states that it was blinded but does not
provide an adequate description of how it was achieved). Studies
that were not double-blind are considered to have high risk of
bias.
• Blinding of outcome assessment (checking for possible
detection bias). We assessed the methods used to blind study
participants and outcome assessors from knowledge of which
intervention a participant received. We assessed the methods as:
low risk of bias (study has a clear statement that outcome
assessors were unaware of treatment allocation, and ideally
describes how this was achieved); unclear risk of bias (study states
that outcome assessors were blind to treatment allocation but
lacks a clear statement on how it was achieved). We judged
studies where outcome assessment was not blinded as having a
high risk of bias.
• Incomplete outcome data (checking for possible attrition
bias due to the amount, nature and handling of incomplete
outcome data). We will assess the methods used to deal with
incomplete data as: low risk (< 10% of participants did not
complete the study and/or used ‘baseline observation carried
forward’ analysis); unclear risk of bias (used ’last observation
carried forward’ analysis); we excluded studies that were high risk
of bias (used ’completer’ analysis).
• Selective reporting (reporting bias). We assessed the risk of
reporting bias as: low risk of bias (all intended outcomes
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reported); unclear risk of bias (any anomaly in reporting, such as
participants contributing more than one set of data, or some
outcomes not participant-reported); we excluded studies that
were high risk of bias (pre-specified outcome of interest not
reported).
• Size of study (Moore 1998; Nuesch 2010), (checking for
possible biases confounded by small size). We assessed studies as
being at low risk of bias (≥ 200 participants per treatment arm);
unclear risk of bias (50 to 199 participants per treatment arm);
high risk of bias (< 50 participants per treatment arm).
We regarded differences in treatment intervention detail (e.g. type
of herbal product/preparation, dosage of herbal product/prepara-
tion or different pain condition) as a potential source of bias as
there was previous evidence of different effects in different neuro-
pathic pain conditions for some interventions (Moore 2009). We
planned to address these in the subgroup analysis, however, the
type of painful condition could not be subjected to a subgroup
analysis due to heterogeneity among the included studies.
We also intended to consider additional risks of bias including
issues of withdrawal (Moore 2010a), and duration (Moore 2010b),
in addition to standard risks of bias.
Measures of treatment effect
For each study, we calculated risk ratio (RR) and 95% confidence
intervals (CI) for dichotomous outcomes, and mean differences
(MD) and 95% CI for continuous outcomes. Only one of the
two included studies provided continuous outcome data, so it was
not necessary to pool different scales to use standardised mean
differences. We used changes from baseline (mean change scores)
in preference to follow-up scores.
Unit of analysis issues
We split the control treatment arm between active treatment arms
in the single study of Motilal 2013, where the active treatment arms
were not combined for analysis, in order to determine individual
treatment effects.
Dealing with missing data
We used intention-to-treat (ITT) analysis wherever possible. The
ITT population consisted of participants who were randomised,
took the assigned herbal product/preparation and provided at least
one post-baseline assessment. We contacted the original investiga-
tors to request missing data by email, with reminder emails sent
when no response was given. For both included studies it was nec-
essary to contact the original authors, however, only one author
provided the requested information despite email and phone call
attempts to the author of the other study.
We did not need to consider missing data during sensitivity anal-
yses.
Standard deviations were available in both studies.
Assessment of heterogeneity
Initially, we qualitatively assessed clinical diversity between the
two studies. We considered whether the studies were similar for
intervention (dosage and duration), type of participant, outcomes
assessed and follow-up time. As we deemed the studies to be clin-
ically homogeneous according to the above terms, we assessed the
data for statistical heterogeneity using RevMan 5 (Review Manager
2014). We used the I² statistic (Higgins 2003), to assess this and
considered values of I² greater than 50% to represent substantial
heterogeneity (Deeks 2017).
Assessment of reporting biases
We contacted study authors when data were not clearly presented
in the papers included in this review. We requested clarification
around what the data were demonstrating as well as the scales used.
When we felt it necessary, we requested raw data from the authors
of the study.
Should it have become apparent that a large enough body of hid-
den data (participants or trials) existed, we would have followed
guidance from the Pain, Palliative and Supportive Care Review
Group and the Cochrane Handbook.
Data synthesis
We considered individual herbal medicinal products/preparations
separately. In order to assess the effectiveness of the intervention
we extracted the dichotomous data from the included studies. We
used these data to calculate risk ratio (RR) or benefit using Review
Manager 2014 with 95% CIs together with numbers needed to
treat for an additional beneficial outcome (NNTBs) (Cook 1995),
using a fixed-effect model, as there was no evidence of heterogene-
ity of effect. We did not calculate the NNTB for pain or the num-
ber needed to treat for an additional harmful outcome (NNTH),
as too few data were available to carry out a meta-analysis. For un-
wanted effects, the NNTB becomes the NNTH and we calculated
this in the same way. We calculated the NNTH for both minor
and major adverse events. Major adverse events are those that lead
to withdrawal from the study. We reported the number and type
of adverse events.
Continuous data were not used as it is inappropriate when there
is an underlying skewed distribution. When continuous data were
used, we used RevMan 5 to report on summary continuous data
where available and appropriate. We carried out a meta-analysis
using a fixed-effect model when there was no evident heterogeneity
of effect.
Meta-analysis was not possible for the primary outcome due to
study heterogeneity and the availability of too few data, therefore
we provided a narrative review.
We attempted to collect outcome assessment data for participants
for all treatment durations and report extracted data as close to
eight weeks as possible but not less than four weeks. Where longer-
duration outcomes were available we also extracted these data.
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Where multiple observations of the same outcome occurred, we ex-
tracted data at clinically relevant time points. This reflected short-
term (immediately after the intervention), medium-term (closest
to 12 weeks) and long-term (24 weeks or more) outcomes.
Quality of the evidence
Two review authors (AB, SMcD) independently rated the quality
of the outcomes. We used the GRADE system to rank the quality
of the evidence using the guidelines provided in the Cochrane
Handbook for Systematic Reviews of Interventions (Schünemann
2017).
The GRADE approach uses five considerations (study limitations,
consistency of effect, imprecision, indirectness and publication
bias) to assess the quality of the body of evidence for each outcome.
The GRADE system uses the following criteria for assigning grade
of evidence.
• High: we are very confident that the true effect lies close to
that of the estimate of the effect.
• Moderate: we are moderately confident in the effect
estimate; the true effect is likely to be close to the estimate of
effect, but there is a possibility that it is substantially different.
• Low: our confidence in the effect estimate is limited; the
true effect may be substantially different from the estimate of the
effect.
• Very low: we have very little confidence in the effect
estimate; the true effect is likely to be substantially different from
the estimate of effect.
We decreased the GRADE rating by one (−1) or two (−2) if we
identified:
• serious (−1) or very serious (−2) limitations to study
quality
• important inconsistency (−1)
• some (−1) or major (−2) uncertainty about directness
• some (-1) or serious (-2) imprecise or sparse data
• high probability of reporting bias (- 1)
’Summary of findings’ table
We included a ’Summary of findings’ table to present the main
findings for herbal products/preparations and neuropathic pain
relief in a transparent and simple tabular format. In particular, we
included key information concerning the quality of evidence, the
magnitude of effect of the interventions examined, and the sum of
available data on the outcomes: participant-reported pain relief of
30% or greater, participant-reported pain relief of 50% or greater,
PGIC much or very much improved, PGIC very much improved,
any pain-related outcome indicating some improvement, with-
drawals and adverse events.
Subgroup analysis and investigation of heterogeneity
Due to the limited number of studies identified fitting the inclu-
sion criteria, there were too few data to carry out subgroup analy-
ses as planned, for:
• type of herbal product/preparation;
• dose of herbal product/preparation;
• concurrent analgesia;
• different painful conditions.
Sensitivity analysis
We did not carry out any sensitivity analysis due to a small evi-
dence base and difficulty in determining the potency of the herbal
products or preparations. We pooled results for different neuro-
pathic pain conditions. We did not carry out any sensitivity anal-
ysis due to a high or unclear risk of bias in the studies.
R E S U L T S
Description of studies
Results of the search
The searches of the five databases retrieved 11,559 records (see
Electronic searches). Our searches of the trials registers identified
35 further studies. Our screening of the reference lists of the in-
cluded publications did not reveal additional RCTs. Our searches
of other resources (e.g. hand searches) identified no additional
studies that appeared to meet the inclusion criteria. We therefore
had a total of 11,594 records.
Once duplicates had been removed, we had a total of 9560 records.
We excluded 8533 records based on titles and a further 1008 based
on abstracts. We obtained the full text of 19 records. We included
two studies (see Characteristics of included studies). We excluded
15 studies (see Characteristics of excluded studies). We added
one record to Characteristics of studies awaiting classification.
We identified one ongoing study (see Characteristics of ongoing
studies).
For a further description of our screening process, see the study
flow diagram (Figure 1).
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Figure 1. Study flow diagram
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Included studies
We included two studies, with 128 participants in total, 91 of
whom were treated with the herbal treatment, in comparison with
placebo (Motilal 2013; Sindrup 2000). These two studies inves-
tigated both diabetic neuropathy (Motilal 2013; Sindrup 2000),
and non-diabetic neuropathic pain conditions (Sindrup 2000).
One study enrolled participants with idiopathic peripheral neu-
ropathy (Sindrup 2000). Whilst both studies enrolled participants
with diabetic neuropathy, only Sindrup 2000 enrolled other non-
diabetic polyneuropathy patients. Study size ranged from 54 to
74 participants with an age range of 21 to 85 years. Both studies
included both men and women.
The studies investigated two herbal medicinal products, namely
nutmeg and St John’s wort. We planned to include studies looking
only at whole plant products or preparations, however, we later
decided that we would also include preparations containing the
active ingredient at a concentration range that would naturally be
present in the plant.
Nutmeg was applied topically as a 125 mL spray for four weeks,
which contained nutmeg oil 14%, methyl salicylate 6%, menthol
6%, mace oil 2%, coconut oil and alcohol (Motilal 2013). St
John’s wort was taken in capsule form containing 900 µg total
hypericin each, which were taken three times daily, giving a total
concentration of 2700 mg (Sindrup 2000); this study lasted for
five weeks.
The exclusion criterion of the identified studies varied slightly
depending on the herbal product/preparation being investigated.
Examples of exclusion criteria applied to these studies were allergies
to the treatment, severe terminal illness, soft tissue infections or
injuries, treatment with monoamine oxidase (MAO) inhibitors,
use of HIV antiretroviral drugs, elderly people or individuals who
may not understand the treatment, or individuals who cannot read
or understand English.
Both studies reported participants to have at least moderate pain
(pain rated as 4 or above on a 10-point numerical rating scale)
at baseline, regardless of the type of neuropathic pain condition.
Pain was reported as having been present for at least three months
in Sindrup 2000, however, Motilal 2013 did not report the actual
duration in included participants. Based on the information given
in this study, we deemed it likely that the majority of participants
in these studies had experienced pain for at least three months (i.e.
chronic pain), and therefore we decided to include it.
Both studies were placebo-controlled without active ingredients.
Placebos took the form of a topical spray of 6% salicylate, 6% men-
thol coconut oil and alcohol (Motilal 2013), and tablets dosed in
the same manner as the total hypericin in Sindrup 2000. Sindrup
2000 used a cross-over design, with a washout period of at least
one week between treatment phases. Motilal 2013 did not specify
any washout period as it was a parallel study.
Both studies allowed continued use of stable oral analgesics, but
all other use of the treatment substance was prohibited.
Excluded studies
We excluded studies if they were non-randomised, case reports
or clinical observations. We excluded 15 studies from this review.
We excluded two studies due to non-randomisation (Mankowski
2017; Staiger 2012). Five studies assessed pain outcomes in
non-neuropathic painful conditions (ISRCTN29199098; Salazar
Sanchez 2010; Wade 2004; Willich 2010; Woolridge 2005). We
excluded two studies based on the fact that the intervention was a
pharmacological agent (Khodari 2017), the second of which used a
treatment of three drugs in the preparation (Barton 2011). We ex-
cluded one study as it did not look at neuropathic pain of a chronic
nature; it investigated the effects of cannabis against heat-induced
acute pain (Abrams 2007). We excluded four studies based on the
rationale that the active ingredient was not present at a concen-
tration that was naturally present in the plant (Hambardzumyan
2017; Moon 2017; Paice 2000; Torre-Mollinedo 2001). We ex-
cluded one study as it did not investigate any of the primary or sec-
ondary outcomes being investigated in this review (Cruccu 2018).
See Characteristics of excluded studies.
Studies awaiting classification
We identified one study that is awaiting classification as the
trial has been completed but it has not yet been fully pub-
lished (NCT02107469 see Characteristics of studies awaiting
classification).
Ongoing studies
We identified one study that is ongoing (IRCT201201248815N1;
see Characteristics of ongoing studies).
Risk of bias in included studies
Comments on potential biases in individual studies are reported in
the ’Risk of bias’ section of the Characteristics of included studies
tables. The findings are displayed in Figure 2 and Figure 3. We
undertook no sensitivity analysis as we judged no studies as having
a low risk of bias. Risk of bias was attributed to small study size
and incomplete outcome data leading to attrition bias.
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Figure 2. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study
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Figure 3. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies
Allocation
Both studies adequately described the method used to generate
the random sequence.
Both studies were randomised and adequately described the
method used to conceal allocation.
Blinding
Blinding of participants and personnel
We judged that both studies were double blind and both reported
the method used.
Blinding of outcome assessment
Both studies clearly identified the participants and outcome asses-
sors remained blind.
Incomplete outcome data
We judged Motilal 2013 as having an unclear risk as they did not
report the amount of missing data and used the last observation
carried forward (LOCF) imputation method for missing data. This
study also recorded a 7% dropout rate.
We judged Sindrup 2000 to be at a high risk of bias as they reported
greater than 10% dropout, with LOCF imputation of data also
being reported.
Selective reporting
Both of the included studies in this review had a low risk of se-
lective reporting bias. Both reported on secondary outcomes in-
cluding any pain-related outcome indicating some improvement,
withdrawals and adverse events. When we contacted primary study
authors, Motilal 2013 provided raw data for pain scores, thereby
allowing us to calculate the number of individuals with a partic-
ipant-reported pain intensity reduction of 30% or greater over
baseline. No anomalies in the reporting of data were evident.
Other potential sources of bias
We considered issues of withdrawal as part of ’incomplete outcome
data’. We could not investigate duration as a source of bias since
both studies only assessed pain immediately post-intervention.
Neither study made any longer-term follow-up assessments.
Size of study
Sindrup 2000 had treatment groups with slightly over 50 partici-
pants randomised per treatment arm. We judged this study as hav-
ing an unclear risk for this item as only 47 participants completed
each arm of the study. Motilal 2013 had more than 50 participants
in total (74) but as it was a parallel study there were only 37 per
treatment arm. We therefore judged this as being at a high risk of
bias.
Effects of interventions
See: Summary of findings for the main comparison Herbal
treatment compared with placebo for adults with neuropathic pain
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See ’Summary of findings’ table 1 for the comparison herbal treat-
ment versus placebo for neuropathic pain (Summary of findings
for the main comparison).
See also Table 1 for the summary of effect in each study.
Primary outcomes
Both included studies reported at least one pain-related outcome
and reported some improvement compared with placebo, as seen
in the data extraction table (Table 1), however, we could not carry
out any meta-analysis due to there only being two studies with het-
erogeneity existing between their primary outcomes. We down-
graded the evidence derived from this review to very low quality
due to limitations in study quality and imprecision. Low study
quality was attributed to various factors such as study size, attri-
tion bias, short duration of intervention and follow-up. For this
reason, we deemed it unnecessary to carry out a subgroup analysis.
Participant-reported pain relief of 30% or greater over
baseline (moderate)
One study reported a participant-reported pain relief of 30% or
above over baseline, in response to nutmeg versus placebo (RR
1.12, 95% CI 0.69 to 1.85; 48.6% vs 43.2%; Motilal 2013).
participant-reported pain relief of 30% or greater over baseline is
a moderate effect as described by the IMMPACT definitions of
moderate and substantial benefit in chronic pain studies (Dworkin
2008), however, this finding was not demonstrative of an effect (P
= 0.64). We downgraded the quality of the evidence by three levels
(using GRADE criteria) to very low due to very serious limitations
in study quality (small participant numbers and attrition bias)
and indirectness (short-term outcomes only). These limitations
caused serious uncertainties about the estimates observed (see
Characteristics of included studies - ’Risk of bias’ tables, Summary
of findings for the main comparison, and additional Table 1).
Participant-reported pain relief of 50% or greater, over
baseline (substantial)
Neither study reported substantial pain relief of 50% or greater.
Participant-reported global impression of clinical change
(PGIC) much or very much improved (moderate)
Neither study reported PGIC much or very much improved.
Participant-reported global impression of clinical change
(PGIC) very much improved (substantial)
Neither study reported PGIC to be very much improved.
Secondary outcomes
Any pain-related outcome indicating some improvement
We attempted to obtain raw data from study authors in order to
calculate percentage change in pain as assessed by VAS, however
only Motilal 2013 provided this information, reporting the mean
values in pain reduction (0 to 100, where 0 = no pain reduction)
and standard deviation (SD) for baseline and post-intervention,
revealing no change between placebo (44 ± 21.5) and nutmeg (44
± 26.5) treatments.
Whilst Sindrup 2000 did not provide raw data, they did report a
lower total pain score in response to St John’s wort compared to
placebo, with a reduction of 1 point from baseline at weeks two
to five on a 0 to 10-point numeric rating scale. This small change
demonstrated no evidence of change between the two groups.
We did not include Sindrup 2000 in Summary of findings for the
main comparison with regards to this secondary outcome as the
author did not provide us with any raw data but reported only
the median pain scores with percentiles as opposed to mean and
standard deviations. Should the author have presented the data to
us, they would have been of limited value due to the downgrading
of the evidence by three levels to very low quality as a result of very
serious limitations to study quality, and indirectness.
Withdrawals
Motilal 2013 observed three withdrawals in response to nutmeg
(3/37; 8%) compared to placebo (2/37; 5%). Reasons were similar
for both groups. In the treatment group, two of the participants
could not be contacted (one after week one and one after week
four), and one had an adverse event, whilst in the placebo group
one could not be contacted after week two and one had an adverse
event. In Sindrup 2000, St John’s wort resulted in 2/54 (4%) with-
drawals (due to loss to follow-up and adverse events) compared to
4/54 (7%) in the placebo group (three were due to lack of efficacy
and one was due to adverse events).
This gave a total of five withdrawals out of 91 participants (5%)
in the treatment groups compared to six withdrawals out of 91
participants (6.5%) in the placebo groups, giving an increased RR
for withdrawal with active treatment (RR 0.83, 95% CI 0.26 to
2.64; NNTH = 1.7; Analysis 1.1). See Summary of findings for
the main comparison.
Again it should be noted that we downgraded the quality of this
evidence by three levels to very low as a result of very serious
limitations in study quality and also indirectness.
Adverse events
Motilal 2013 documented four adverse events recorded in those
who were treated with nutmeg (37 participants), whilst two ad-
verse events were reported in the placebo group (37 participants).
17Herbal medicinal products or preparations for neuropathic pain (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Sindrup 2000 reported that St John’s wort resulted in 13 adverse
events in the treatment group (54 participants) and 15 in the
placebo group (54 participants). When we combined these stud-
ies, we observed a RR of 1.00 (95% CI 0.55 to 1.81; NNTH =
10; Analysis 2.1), for adverse events in response to these herbal
treatments, and an odds ratio of 1.00 (95% CI 0.47 to 2.15). See
Summary of findings for the main comparison.
Additional adverse events noted with nutmeg treatment were mild,
transient and tolerable, and there were no major systemic adverse
events (Motilal 2013). Adverse events were also few with the dose
of St John’s wort and were not different in spectrum and severity
from adverse events reported with placebo (Sindrup 2000). This
is in line with previous observations with St John’s wort (Ernst
2001). However, we downgraded the quality of the evidence for
this outcome to very low as a result of very serious limitations in
study quality and also indirectness.
Neither study documented any deaths or serious adverse events.
D I S C U S S I O N
Summary of main results
Summary of findings for the main comparison outlines the main
results of this review by highlighting the effects of herbal medici-
nal products or preparations on each primary and secondary out-
come. The main findings demonstrate a RR of 1.12 (95% CI
0.69 to 1.85), for the primary outcome of ’number of participants
obtaining 30% pain relief over baseline’ in response to treatment
(nutmeg) compared to placebo. The secondary outcome of ’any
pain-related outcome indicating some improvement’ highlighted
no difference between treatment (nutmeg) and placebo when it
was assessed on a VAS. We observed a RR of 0.83 (95% CI 0.26
to 2.64) for the secondary outcome ’study withdrawals’ between
treatment and control. Finally, adverse events were no different
between treatment and placebo (RR 1.00, 95% CI 0.55 to 1.81).
All of the main findings reported in this review are limited in
their meaningfulness as we downgraded all primary and secondary
outcomes to very low quality (Summary of findings for the main
comparison). We have little confidence in the findings as the qual-
ity of the evidence is too low to draw any definitive conclusions.
Overall completeness and applicability of
evidence
Based on the evidence collated in this review, it is not possible to
draw any meaningful conclusions. Whilst the evidence presented
in this review is relevant to the research question in that it examines
the effects of herbal medicinal products towards neuropathic pain,
overall, the evidence presented is of very low quality and therefore
does not permit the research question or indeed the objectives, to
be answered. The studies were carried out with low participant
numbers and with only one condition. This prevented the pooling
of studies, resulting in little confidence about effects or size of
effect observed. In addition, both studies were of short duration
(maximum of five weeks), so it was not possible to assess whether
any early response would be maintained in the longer term. This is
important in chronic conditions. The outcomes investigated in the
studies were also limited in that they mainly reported secondary
outcomes.
In summary, the evidence presented in this review was trivial
in amount and therefore is not applicable to clinical practice
at this stage. Further studies of higher quality, in larger num-
bers of participants, across a number of neuropathic pain con-
ditions and looking at primary pain outcomes as specified by
IMMPACT, are required (Dworkin 2008). These should also be
carried out over longer follow-up time points in order to an-
swer the research question looking at the effect of herbal medic-
inal products or preparations on neuropathic pain and to assess
the analgesic efficacy and effectiveness of herbal medicinal prod-
ucts or preparations for neuropathic pain, and also the adverse
events they may cause. We anticipate that the two studies listed
as ongoing (IRCT201201248815N1), and awaiting classification
(NCT02107469), will provide limited evidence to answer the
research question due to the low quality of the evidence their
methodology will allow.
Quality of the evidence
Both studies were randomised and double-blind, with one of the
two studies providing primary outcome data, the other only pro-
viding secondary outcome data. We could carry out meta-analysis
only for withdrawals and adverse events (secondary outcomes).
We downgraded the quality of the evidence three times to very low
using the GRADE approach. This prevented us from drawing any
conclusions about the effects of the herbal treatments investigated
in the studies. We have very little confidence in the effect estimate,
and the true effect is likely to be substantially different from the
estimate of effect.
Small study size, a large number of dropouts and missing data (at-
trition bias), as well as short study duration, caused us to down-
grade evidence twice for very serious study limitations. The stud-
ies assessed outcomes only at baseline and immediately after treat-
ment. There were no follow-up outcomes after this time point
and the actual interventions themselves were of short duration
(four and five weeks) with a lack of follow-up time points to assess
longer-term effects of the intervention after the treatment phase.
For this reason we downgraded the quality of the evidence a fur-
ther level due to indirectness.
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Potential biases in the review process
We carried out a broad search for studies, and think it is unlikely
that significant numbers of studies remain unknown to us regard-
ing the efficacy of herbal medicinal products or preparations in
neuropathic pain conditions. We attempted to identify medicinal
herbal products or preparations being used without sufficient evi-
dence of effectiveness (unpublished data) by contacting experts in
the field of complementary and alternative medicine.
We contacted study authors to request information surrounding
the results presented in the papers in addition to the raw data if we
deemed it essential. Whilst only one out of the two study authors
responded to this request, we do not feel it would have changed
the outcome of this review as we classed both studies as very low
quality regardless of this information.
Agreements and disagreements with other
studies or reviews
The evidence collated in this review is of very low quality and
also very limited, and therefore making comparisons of agreement
or disagreement with other studies is difficult. The results of a
Cochrane Review investigating the effects of capsaicin on neuro-
pathic pain relief suggested that capsaicin applied repeatedly at a
low dose (0.075% cream), or as a single application of a high dose
(8% patch), may provide a degree of pain relief to some individuals
(Derry 2009). However, similar to the current review, estimates
of benefit and harm were not robust due to limited amounts of
data for different neuropathic conditions in addition to having
inconsistent outcome definitions. By way of adverse events and
withdrawals, local skin irritation resulting from capsaicin led to
some withdrawals, which were common but were often mild and
transient, which again is similar to our observations for nutmeg
and St John’s wort in this review. Systemic adverse events were also
rare for capsaicin.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
For people with neuropathic pain
There was insufficient evidence to suggest that nutmeg or St John’s
wort has any efficacy in any neuropathic pain conditions. The
current evidence is of very low quality resulting in serious uncer-
tainties about the estimates of effect observed. The evidence on
adverse events is very low quality and therefore caution should be
applied to its usage until more research has been done in this area.
For clinicians
There was insufficient evidence to suggest that nutmeg or St John’s
wort has any efficacy in any neuropathic pain conditions. The
current evidence is of very low quality resulting in serious uncer-
tainties about the estimates of effect observed.
For policy makers
There was insufficient evidence to suggest that nutmeg or St John’s
wort has any efficacy in any neuropathic pain conditions and there-
fore should not be recommended by policy makers at present. Fur-
ther clinical trials are necessary.
For funders
There was insufficient evidence to suggest that nutmeg or St John’s
wort has any efficacy in any neuropathic pain conditions. The
body of the evidence from the two included studies is of too low
quality, resulting in serious uncertainties about the estimates of
effect observed. Establishing whether these particular herbal prod-
ucts/preparations, or indeed any other herbal product or prepara-
tion, have any efficacy would require large clinical trials in several
types of neuropathic pain. The evidence surrounding the adverse
events associated with current pharmacological treatments for spe-
cific types of neuropathic pain and the knowledge that people
with this type of pain are likely to try herbal treatments are both
justification for further clinical trials investigating the safety and
efficacy of herbal medicines in the treatment of such conditions.
To ascertain whether pain relief is brought about as a result of
nutmeg and St John’s wort requires development of the evidence




Nutmeg and St John’s wort have only been investigated in one
study each and therefore more studies are required to draw any
conclusions on these types of herbal products or preparations.
Randomised controlled trials (RCTs) of adequate sample size (i.e.
more than 200 participants per treatment arm), duration (longer
than 12 weeks), with analysis that does not use imputation meth-
ods are required to establish whether herbal medicinal products
are effective in reducing neuropathic pain. The two studies that
are listed as ongoing (IRCT201201248815N1), or awaiting clas-
sification (NCT02107469), will not address this review question
any more clearly than those published studies that are reported
within this review. The reasons for this are outlined below. We
recognise, however, that although further studies would be desir-
able, it is unlikely that there will be interest to fund these.
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Design
Studies of cross-over design with comparison to placebo, no inter-
vention or active comparator and assessing a large study population
are required. In addition, studies should be carried out in partici-
pants suffering from various types of neuropathic pain and should
include long-term follow-up assessment of efficacy. Outcome mea-
sures should be collected at baseline, at regular meaningful time-
points and at the end of the study. Longer duration studies are
required to assess the meaningfulness of any efficacy that might be
observed in response to herbal medicinal products. The two studies
in this review do not include follow-up assessment past two months
and therefore this highlights the need for further longer-term stud-
ies. Those studies that are ongoing (IRCT201201248815N1),
or awaiting classification (NCT02107469), in this area investi-
gate the effects of ajwain cream and Phyllanthus niruri and Sida
cordifolia towards neuropathic pain via double-blind randomised
placebo-controlled trials in participants with neuropathic pain di-
agnosis as a result of diabetic peripheral polyneuropathy and also
postsurgical/post-traumatic neuropathic pain. These studies did
not record outcomes past eight weeks.
Measurement (endpoints)
The measurements or outcomes assessed by the studies included in
the current review were mostly secondary outcomes that are recom-
mended by IMMPACT, with no data being extracted for primary
outcomes aside from 30% pain relief or greater. Future research
is needed to investigate these primary outcomes of neuropathic
pain management, namely the number of participants obtaining
50% pain relief or greater over baseline, the number of participants
obtaining 30% pain relief or greater over baseline, participant-re-
ported global impression of clinical change (PGIC) much or very
much improved (moderate) and participant-reported global im-
pression of clinical change (PGIC) very much improved (substan-
tial). The ongoing study (IRCT201201248815N1), and study
awaiting classification (NCT02107469), also used secondary mea-
sures of pain assessment as opposed to those listed as primary out-
comes by IMMPACT.
Other
Due to the limited number of trials, with few participants, inves-
tigating whole plant herbal products/preparations, there is a clear
need for large, good-quality, long-duration, RCTs in participants
suffering from various types of neuropathic pain. These have been
done in other chronic conditions (Mills 1996; Oltean 2014), but
not of a neuropathic nature. The number of participants investi-
gated in the ongoing study IRCT201201248815N1 and the study
awaiting classification, NCT02107469 does not exceed 200 and
this, therefore, still poses a high risk of bias, lowering the method-
ological quality of both studies.
Motilal 2013 was the first clinical trial to be carried out on nutmeg,
and therefore further human studies are required on the evidence
base, however, the cost of these trials would be at least several
million GBP, USD, or EUR. To date, all evidence supporting
the analgesic effects of nutmeg has been demonstrated in animal
models only (Hayfaa 2013; Sonavane 2001; Zhang 2016).
This review found no high-quality evidence from good-quality
RCTs to support the use of herbal medicinal products and prepa-
rations for neuropathic pain. Further research is very likely to have
an important impact on our confidence in the estimate of effect
and is likely to change the estimate.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Motilal 2013
Methods Randomised, double-blind, placebo-controlled trial
Participants Adults aged 21-85 years, with PDN of: hands (5.4% NEMM), feet (51.4% NEMM;
67.6% MM), both (43.2% NEMM; 32.4% MM)
Symptoms limited to the extremities of limbs, and an average neuropathic pain > 4 as
determined by the DN4 questionnaire
n = 74 (37/arm)
M 24 (32.4%): F 50 (67.6%)
Mean (SD) age: NEMM 60.7 (11.5) years, MM 59.7 (8.1) years
Interventions Treatment
Commercially available topical preparation of nutmeg extracts (NEMM). Colourless
with same odour as MM in 125 mL spray bottle
Participants instructed to apply 4 sprays to affected area 3 times/day, followed by gentle
massage for 4 weeks
Control
Placebo (MM). Colourless with same odour as NEMM, in 125 mL spray bottle
Participants instructed to apply 4 sprays to affected area 3 times/day, followed by gentle
massage for 4 weeks
Outcomes Worst or average pain as measured by BPI for PDN and total NPSI score




Method of delivery Topical via spray
Exclusion criteria Soft-tissue infections and injuries, radiating cervical or lumbosacral pain, tendinitis,
spurs, broken skin or rash at pain sites and salicylate allergy
Notes Noelville Ltd, Grenada agreed to manufacture and supply both the treatments and
placebos used in this trial. University of West Indies (Trinidad) - St Augustine Campus
financially supported the study
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Random-number-generating software used
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Motilal 2013 (Continued)
Allocation concealment (selection bias) Low risk Sealed envelopes each containing 1-80 cho-
sen at random by participant
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk All treatments were in similar 125 mL spray
bottles with contents colourless and same
viscosity. Odours same
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk All scoring of the primary outcome, NPSI,
were measured by a blinded assessor
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Doesn’t state how much data is missing.
LOCF used for missing data. 7% dropout
Selective reporting (reporting bias) Low risk Primary and secondary outcome data were
reported
Size High risk n = 74 participants in total but n = 37 per
treatment arm
Sindrup 2000
Methods Randomized, double-blind, placebo-controlled and cross-over
Participants Adults > 20 years, mean of 58 years (30-82), with painful polyneuropathy (idiopathic
n = 17, diabetic n = 18, alcohol n = 1, drug-induced n = 5, others n = 6) confirmed by
electrophysiological tests for > 6 months
n = 54 entered and 47 completed trial
Interventions Treatment
St John’s wort: 3 tablets (900 µg total hypericin each); total daily dose 2700 mg total
hypericin given in the evening x 5 weeks
Control
Placebo (3 tablets identical in appearance were dosed similarly in the placebo phase) x 5
weeks
At least 1 week washout
≤ 6 tablets of 500 mg paracetamol could be used daily as escape medication during all
study phases
Outcomes Total pain score and lancinating pain for St Johns wort vs placebo, total and individual
pain scores between groups
Withdrawals
AEs
Follow-up • Daily - primary and secondary outcome
• Baseline, end of each phase - pain objective measures
• Side-effects - end of each phase
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Sindrup 2000 (Continued)
Method of delivery Oral
Exclusion criteria Causes of pain other than polyneuropathy, previous allergic reactions to St John’s wort,
treatment with MAO inhibitors, pregnancy, severe terminal illness
Notes SanoPharm A/S, Denmark provided study drugs. The Foundation of 1870 and the
Danish National Research Council (NASTRA grant no. 42820) financially supported
the study
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated block size of 4
Allocation concealment (selection bias) Low risk Study drugs were packed in boxes marked
with participant number and treatment pe-
riod
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Treatment and placebo were identical
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcome assessor blinded to treatment al-
location of participant
Incomplete outcome data (attrition bias)
All outcomes
High risk LOCF for 13% dropout
Selective reporting (reporting bias) Low risk Secondary pain-related outcome indicating
some improvement and other secondary
outcomes reported
Size Unclear risk n = 54 participants
AE: adverse event; BPI: Brief Pain Inventory; CI: confidence interval; DN: Douleur Neuropathique; F: female; LOCF: last outcome
carried forward; M: male; MAO: monoamine oxidase mL: millilitres; MM: methyl salicylate (6%), menthol (6%), coconut oil,
alcohol; n: number of participants; NEMM: nutmeg oil (14%), methyl salicylate (6%), menthol (6%), mace oil (2%), coconut oil,
alcohol; NPSI: Neuropathic Pain Symptom Inventory; PDN: painful diabetic neuropathy; RR: risk ratio; SD: standard deviation;
µg: microgram
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Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Abrams 2007 Acute pain not chronic
Barton 2011 Combination of 3 drugs, not a whole plant medicinal product
Cruccu 2018 Did not look at primary or secondary neuropathic pain outcomes
Hambardzumyan 2017 Active ingredient not present in the concentration naturally present in the plant
ISRCTN29199098 Not neuropathic pain
Khodari 2017 Pharmacological topical agent not plant
Mankowski 2017 Not an RCT
Moon 2017 Active ingredient not present in the concentration naturally present in the plant
Paice 2000 Active ingredient not present in the concentration naturally present in the plant
Salazar Sanchez 2010 Not neuropathic pain
Staiger 2012 Not an RCT
Torre-Mollinedo 2001 Active ingredient not present in the concentration naturally present in the whole plant
Wade 2004 Not neuropathic pain
Willich 2010 Not neuropathic pain
Woolridge 2005 Not neuropathic pain
RCT: randomised controlled trial
Characteristics of studies awaiting assessment [ordered by study ID]
NCT02107469
Methods Randomised, double-blind, parallel
Participants 98 men and women aged 20-80 years
Interventions Phyllanthus niruri 3 g fine dry powder 3 times/day and Sida cordifolia 7 g coarse dry powder 2 times/day for 8 weeks
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NCT02107469 (Continued)
Outcomes Improvement of NTSS-6 in % from baseline, validated symptom score containing 6 questions investigation severity
Notes NCT02107469
g: gram; NTSS: Neuropathy Total Symptom Score
Characteristics of ongoing studies [ordered by study ID]
IRCT201201248815N1
Trial name or title Evaluation of ajwain cream in participants with neuropathic foot, a double blind randomized controlled
clinical trial
Methods Randomised, double-blind, parallel
Participants 92 men and women
Interventions Ajwain cream (5 cm of cream on the affected area of feet twice/day for 30 days)
Outcomes Change or any decline in foot burn in neuropathic foot
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D A T A A N D A N A L Y S E S
Comparison 1. Herbal treatment versus placebo




participants Statistical method Effect size
1 Study withdrawals 2 182 Risk Ratio (M-H, Fixed, 95% CI) 0.83 [0.26, 2.64]
Comparison 2. Herbal treatment versus placebo




participants Statistical method Effect size
1 Adverse events 2 182 Risk Ratio (M-H, Fixed, 95% CI) 1.0 [0.55, 1.81]
Analysis 1.1. Comparison 1 Herbal treatment versus placebo, Outcome 1 Study withdrawals.
Review: Herbal medicinal products or preparations for neuropathic pain
Comparison: 1 Herbal treatment versus placebo




Treatment Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Sindrup 2000 2/54 4/54 66.7 % 0.50 [ 0.10, 2.62 ]
Motilal 2013 3/37 2/37 33.3 % 1.50 [ 0.27, 8.46 ]
Total (95% CI) 91 91 100.0 % 0.83 [ 0.26, 2.64 ]
Total events: 5 (Favours Herbal Treatment), 6 (Placebo)
Heterogeneity: Chi2 = 0.81, df = 1 (P = 0.37); I2 =0.0%
Test for overall effect: Z = 0.31 (P = 0.76)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours Herbal Treatment Favours Placebo
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Analysis 2.1. Comparison 2 Herbal treatment versus placebo, Outcome 1 Adverse events.
Review: Herbal medicinal products or preparations for neuropathic pain
Comparison: 2 Herbal treatment versus placebo
Outcome: 1 Adverse events
Study or subgroup Herbal Treatment Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Motilal 2013 4/37 2/37 11.8 % 2.00 [ 0.39, 10.26 ]
Sindrup 2000 13/54 15/54 88.2 % 0.87 [ 0.46, 1.64 ]
Total (95% CI) 91 91 100.0 % 1.00 [ 0.55, 1.81 ]
Total events: 17 (Herbal Treatment), 17 (Placebo)
Heterogeneity: Chi2 = 0.88, df = 1 (P = 0.35); I2 =0.0%
Test for overall effect: Z = 0.0 (P = 1.0)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours Herbal Treatment Favours Placebo
A D D I T I O N A L T A B L E S
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AE: adverse event; BPI: Brief Pain Inventory; CI: confidence interval; DN: Douleur Neuropathique; LOCF: last outcome carried
forward; mL: millilitres; MM: methyl salicylate (6%), menthol (6%), coconut oil, alcohol; n: number of participants; NEMM:
nutmeg oil (14%), methyl salicylate (6%), menthol (6%), mace oil (2%), coconut oil, alcohol; NPSI: Neuropathic Pain Symptom
Inventory; PDN: painful diabetic neuropathy; RR: risk ratio; µg: microgram
A P P E N D I C E S
Appendix 1. CENTRAL search strategy
1. MeSH descriptor: [Herbal Medicine] this term only
2. MeSH descriptor: [Medicine, Traditional] this term only
3. MeSH descriptor: [Plant Extracts] this term only
4. MeSH descriptor: [Plant Preparations] explode all trees
5. MeSH descriptor: [Complementary Therapies] this term only
6. MeSH descriptor: [Phytotherapy] this term only
7. (herb or herbs or herbal):ti,ab,kw (Word variations have been searched)
8. (herbal near/5 medicine*):ti,ab,kw (Word variations have been searched)
9. (traditional near/5 medicine*):ti,ab,kw (Word variations have been searched)
10. (plant* near/5 extract*):ti,ab,kw (Word variations have been searched)
11. (plant* near/5 preparation*):ti,ab,kw (Word variations have been searched)
12. (herb* near/5 tea*):ti,ab,kw (Word variations have been searched)
13. (plant* near/5 oil*):ti,ab,kw (Word variations have been searched)
14. (complementary near/5 therap*):ti,ab,kw (Word variations have been searched)
15. (alternative near/5 therap*):ti,ab,kw (Word variations have been searched)
16. (phytotherap* or homeopath*):ti,ab,kw (Word variations have been searched)
17. (herbal near/5 drug*):ti,ab,kw (Word variations have been searched)
18. (medicinal near/5 herb*):ti,ab,kw (Word variations have been searched)
19. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18
20. MeSH descriptor: [Pain] explode all trees
21. MeSH descriptor: [Peripheral Nervous System Diseases] explode all trees
22. MeSH descriptor: [Somatosensory Disorders] explode all trees
23. MeSH descriptor: [Myofascial Pain Syndromes] explode all trees
33Herbal medicinal products or preparations for neuropathic pain (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
24. MeSH descriptor: [Polymyalgia Rheumatica] this term only
25. ((pain* or discomfort*) near/10 (central or complex or rheumat* or muscl* or muscul* or myofasci* or nerv* or neuralg* or
neuropath*)):ti,ab,kw (Word variations have been searched)
26. ((neur* or nerv*) near/6 (compress* or damag*)):ti,ab,kw (Word variations have been searched)
27. 20 or 21 or 22 or 23 or 24 or 25 or 26
28. 27 and 19
Appendix 2. MEDLINE search strategy
MEDLINE (OVID)
1 Herbal Medicine/ (1793)
2 Medicine, Traditional/ (10088)
3 Plant Extracts/ (95457)
4 exp Plant Preparations/ (192252)
5 Complementary Therapies/ (15775)
6 Phytotherapy/ (35713)
7 (herb or herbs or herbal).ab,kw,ti. (37463)
8 (herbal adj5 medicine$).ab,kw,ti. (9904)
9 (traditional adj5 medicine$).ab,kw,ti. (24774)
10 (plant$ adj5 extract$).ab,kw,ti. (14675)
11 (plant$ adj5 preparation$).ab,kw,ti. (1451)
12 (herb$ adj5 tea$).ab,kw,ti. (946)
13 (plant$ adj5 oil$).ab,kw,ti. (3737)
14 (complementary adj5 therap$).ab,kw,ti. (4529)
15 (alternative adj5 therap$).ab,kw,ti. (22804)
16 (phytotherap$ or homeopath$).ab,kw,ti. (5773)
17 (herbal adj5 drug$).ab,kw,ti. (2278)
18 (medicinal adj5 herb$).ab,kw,ti. (4167)
19 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 (277813)
20 exp PAIN/ (354243)
21 exp PERIPHERAL NERVOUS SYSTEM DISEASES/ (134931)
22 exp SOMATOSENSORY DISORDERS/ or exp MYOFASCIAL PAIN SYNDROMES/ or POLYMYALGIA RHEUMATICA/
(28056)
23 ((pain* or discomfort*) adj10 (central or complex or rheumat* or muscl* or muscul* or myofasci* or nerv* or neuralg* or neu-
ropath*)).mp. (78160)
24 ((neur* or nerv*) adj6 (compress* or damag*)).mp. (56235)
25 20 or 21 or 22 or 23 or 24 (538660)
26 randomized controlled trial.pt. (454574)
27 controlled clinical trial.pt. (92184)
28 randomized.ab. (353744)
29 placebo.ab. (170695)




34 exp animals/ not humans.sh. (4430952)
35 33 not 34 (2411193)
36 19 and 25 and 35 (2863)
37 (201612* or 2017* or 2018*).ed. (1108476)
38 36 and 37 (229)
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Appendix 3. Embase search strategy
1 *Herbal Medicine/ (8118)
2 *Medicine, Traditional/ (8640)
3 *Plant Extracts/ (81005)
4 exp *Plant Medicinal Product/ (682022)
5 *Complementary Therapies/ (18404)
6 *Phytotherapy/ (9512)
7 (herb or herbs or herbal).ab,kw,ti. (70708)
8 (herbal adj5 medicine$).ab,kw,ti. (19383)
9 (traditional adj5 medicine$).ab,kw,ti. (47620)
10 (plant$ adj5 extract$).ab,kw,ti. (30237)
11 (plant$ adj5 preparation$).ab,kw,ti. (2241)
12 (herb$ adj5 tea$).ab,kw,ti. (1626)
13 (plant$ adj5 oil$).ab,kw,ti. (6555)
14 (complementary adj5 therap$).ab,kw,ti. (8208)
15 (alternative adj5 therap$).ab,kw,ti. (37968)
16 (phytotherap$ or homeopath$).ab,kw,ti. (10435)
17 (herbal adj5 drug$).ab,kw,ti. (5717)
18 (medicinal adj5 herb$).ab,kw,ti. (8032)
19 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 (816908)
20 exp PAIN/ (1125569)
21 exp PERIPHERAL NERVOUS SYSTEM DISEASES/ (63250)
22 exp SOMATOSENSORY DISORDERS/ (85464)
23 exp MYOFASCIAL PAIN SYNDROMES/ or POLYMYALGIA RHEUMATICA/ (10793)
24 ((pain* or discomfort*) adj10 (central or complex or rheumat* or muscl* or muscul* or myofasci* or nerv* or neuralg* or neu-
ropath*)).mp. (155761)
25 ((neur* or nerv*) adj6 (compress* or damag*)).mp. (85034)




30 cross over$.tw. (28907)
31 cross-over$.tw. (28907)
32 placebo$.tw. (269611)
33 (doubl$ adj blind$).tw. (186897)




38 Crossover Procedure/ (54565)
39 double-blind procedure.tw. (239)
40 Randomized Controlled Trial/ (490541)
41 Single Blind Procedure/ (30578)
42 or/27-41 (1964186)
43 (animal/ or nonhuman/) not human/ (5476035)
44 42 not 43 (1744410)
45 19 and 26 and 44 (8107)
46 (201612* or 2017* or 2018*).dd. (1640185)
47 45 and 46 (519)
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Appendix 4. CINAHL search strategy
S38 S36 AND S37
S37 20161201-20180314
S36 S29 AND S38
S35 S27 OR S28 OR S29 OR S30 OR S31 OR S32 OR S33 OR S34
S34 (allocat* random*)




S29 (MH “Random Assignment”)
S28 (Randomi?ed control* trial*)
S27 (singl* blind* ) or (doubl* blind* ) or (tripl* blind* ) or (trebl* blind* ) or (trebl* mask* ) or (tripl* mask* ) or (doubl* mask* ) or
(singl* mask* ) S29 S17 AND S28
S26 S18 OR S19 OR S20 OR S21 OR S22 OR S23 OR S24 OR S25
S25 FM or FMS
S24 ((neur* or nerv*) n6 (compress* or damag*))
S23 ((pain* or discomfort*) N10 (central or complex or rheumat* or muscl* or muscul* or myofasci* or nerv* or neuralg* or neuropath*))
S22 (MH “Polymyalgia Rheumatica”)
S21 (MH “Myofascial Pain Syndromes+”)
S20 (MH “Somatosensory Disorders+”)
S19 (MH “Peripheral Nervous System Diseases+”)
S18 (MH “Pain+”)
S17 S1 OR S2 OR S3 OR S4 OR S5 OR S6 OR S7 OR S8 OR S9 OR S10 OR S11 OR S12 OR S13 OR S14 OR S15 OR S16
S16 (medicinal n5 herb*)
S15 (herbal n5 drug*)
S14 (phytotherap* or homeopath*)
S13 (alternative n5 therap*)
S12 (complementary n5 therap*)
S11 (plant* n5 oil*)
S10 (herb* n5 tea*)
S9 (plant* n5 preparation*)
S8 (plant* n5 extract*)
S7 (traditional n5 medicine*)
S6 (herbal n5 medicine*)
S5 (herb or herbs or herbal)
S4 (MH “Alternative Therapies”)
S3 (MH “Plant Extracts”)
S2 (MH “Medicine, Traditional”)
S1 (MH “Medicine, Herbal”)
Appendix 5. AMED search strategy
1 Plant Extracts/ (17424)
2 Complementary Therapies/ (3906)
3 Phytotherapy/ (4745)
4 (herb or herbs or herbal).ab,kw,ti. (4989)
5 (herbal adj5 medicine$).ab,kw,ti. (1550)
6 (traditional adj5 medicine$).ab,kw,ti. (3153)
7 (plant$ adj5 extract$).ab,kw,ti. (1632)
8 (plant$ adj5 preparation$).ab,kw,ti. (154)
9 (herb$ adj5 tea$).ab,kw,ti. (87)
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10 (plant$ adj5 oil$).ab,kw,ti. (220)
11 (complementary adj5 therap$).ab,kw,ti. (1268)
12 (alternative adj5 therap$).ab,kw,ti. (1076)
13 (phytotherap$ or homeopath$).ab,kw,ti. (4068)
14 (herbal adj5 drug$).ab,kw,ti. (338)
15 (medicinal adj5 herb$).ab,kw,ti. (504)
16 exp PAIN/ (20678)
17 exp MYOFASCIAL PAIN SYNDROMES/ or POLYMYALGIA RHEUMATICA/ (430)
18 ((pain* or discomfort*) adj10 (central or complex or rheumat* or muscl* or muscul* or myofasci* or nerv* or neuralg* or neu-
ropath*)).mp. (6478)
19 ((neur* or nerv*) adj6 (compress* or damag*)).mp. (910)
20 16 or 17 or 18 or 19 (23759)
21 or/1-15 (32073)
22 20 and 21 (1072)
23 limit 22 to yr=“2016 -Current” (41)
W H A T ’ S N E W
Date Event Description
3 April 2019 Amended ’Next stage expected’ date amended.
H I S T O R Y
Protocol first published: Issue 5, 2013
Review first published: Issue 3, 2019
Date Event Description
11 July 2017 Amended This protocol has been reinstated following withdrawal and we have made the following amendments:
• removed fibromyalgia in line with current PaPaS policy;
• removed cannabinoids as this is the topic of another Cochrane Review;
• updated background text and references;
• added GRADE methods wording and removed tiers of evidence;
• added selective outcome reporting to risk of bias methods.
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C O N T R I B U T I O N S O F A U T H O R S
AB, SMcD and CB wrote the protocol. AB and CB carried out searches and assessed studies for inclusion. AB and DH extracted data.
SMcD acted as arbitrator. All authors reviewed the protocol and were involved in writing the review. AB drafted the final write-up. AB
will be responsible for updating the review. PB acted as a content expert.






PB is a retired consultant in pain medicine who has treated patients with neuropathic pain in the past. She received funding from
Grunenthal pharmaceutical company in 2017.
SMcD: none known
S O U R C E S O F S U P P O R T
Internal sources
• No sources of support supplied
External sources
• Health and Social Care Research and Development Division of the Public Health Agency (Northern Ireland) - Cochrane
Fellowship, UK.
D I F F E R E N C E S B E T W E E N P R O T O C O L A N D R E V I E W
The protocol for this review was reinstated following withdrawal, and we made the following amendments.
• Removed fibromyalgia in line with PaPaS policy to separate the two conditions.
• We excluded studies monitoring the effects of cannabinoids/cannabis or capsaicin as these have now been dealt with in separate
Cochrane Reviews (Mücke 2016 (cannabis); Derry 2012; Derry 2013 (capsaicin)). As we have now excluded cannabis studies from
this review, we included only orally or topically applied herbal products or preparations.
• Updated background text and references.
• Added GRADE methods wording and removed tiers of evidence.
• Added selective outcome reporting to risk of bias methods, and also assessed both performance and detection bias.
• We decided to include preparations containing the active ingredient at a concentration range that would naturally be present in
the plant.
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I N D E X T E R M S
Medical Subject Headings (MeSH)
∗Phytotherapy; Analgesics [therapeutic use]; Chronic Pain [∗drug therapy]; Neuralgia [∗drug therapy]; Plant Extracts [∗therapeutic
use]; Randomized Controlled Trials as Topic; Treatment Outcome
MeSH check words
Adult; Humans
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